Literature DB >> 31939786

Effect of Best Practice Advisories on Sedation Protocol Compliance and Drug-Related Hazardous Condition Mitigation Among Critical Care Patients.

Rebecca A Greene1, Andrew R Zullo1,2,3, Craig M Mailloux4, Christine Berard-Collins1, Mitchell M Levy5, Timothy Amass5.   

Abstract

OBJECTIVES: To determine whether best practice advisories improved sedation protocol compliance and could mitigate potential propofol-related hazardous conditions.
DESIGN: Retrospective observational cohort study.
SETTING: Two adult ICUs at two academic medical centers that share the same sedation protocol. PATIENTS: Adults 18 years old or older admitted to the ICU between January 1, 2016, and January 31, 2018, who received a continuous infusion of propofol.
INTERVENTIONS: Two concurrent best practice advisories built in the electronic health record as a clinical decision support tool to enforce protocol compliance with triglyceride and lipase level monitoring and mitigate propofol-related hazardous conditions.
MEASUREMENTS AND MAIN RESULTS: The primary outcomes were baseline and day 3 compliance with triglyceride and lipase laboratory monitoring per protocol and time to discontinuation of propofol in the setting of triglyceride and/or lipase levels exceeding protocol cutoffs. A total of 1,394 patients were included in the study cohort (n = 700 in the pre-best practice advisory group; n = 694 in the post-best practice advisory group). In inverse probability weighted regression analyses, implementing the best practice advisory was associated with a 56.6% (95% CI, 52.6-60.9) absolute increase and a 173% relative increase (risk ratio, 2.73; 95% CI, 2.45-3.04) in baseline laboratory monitoring. The best practice advisory was associated with a 34.0% (95% CI, 20.9-47.1) absolute increase and a 74% (95% CI, 1.39-2.19) relative increase in day 3 laboratory monitoring after inverse probability weighted analyses. Among patients with laboratory values exceeding protocol cutoffs, implementation of the best practice advisory resulted in providers discontinuing propofol an average of 16.6 hours (95% CI, 4.8-28.3) sooner than pre-best practice advisory. Findings from alternate analyses using interrupted time series were consistent with the inverse probability weighted analyses.
CONCLUSIONS: Best practice advisories can be effectively used in ICUs to improve sedation protocol compliance and may mitigate potential propofol-related hazardous conditions. Best practice advisories should undergo continuous quality assurance and optimizations to maximize clinical utility and minimize alert fatigue.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31939786      PMCID: PMC8840326          DOI: 10.1097/CCM.0000000000004116

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  27 in total

Review 1.  Incidence of medication errors and adverse drug events in the ICU: a systematic review.

Authors:  Amanda Wilmer; Kimberley Louie; Peter Dodek; Hubert Wong; Najib Ayas
Journal:  Qual Saf Health Care       Date:  2010-07-29

2.  Forum on aging and skeletal health: summary of the proceedings of an ASBMR workshop.

Authors:  Sundeep Khosla; Teresita M Bellido; Marc K Drezner; Catherine M Gordon; Tamara B Harris; Douglas P Kiel; Barbara E Kream; Meryl S LeBoff; Jane B Lian; Charlotte A Peterson; Clifford J Rosen; John P Williams; Karen K Winer; Sherry S Sherman
Journal:  J Bone Miner Res       Date:  2011-09-13       Impact factor: 6.741

3.  Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.

Authors:  John W Devlin; Yoanna Skrobik; Céline Gélinas; Dale M Needham; Arjen J C Slooter; Pratik P Pandharipande; Paula L Watson; Gerald L Weinhouse; Mark E Nunnally; Bram Rochwerg; Michele C Balas; Mark van den Boogaard; Karen J Bosma; Nathaniel E Brummel; Gerald Chanques; Linda Denehy; Xavier Drouot; Gilles L Fraser; Jocelyn E Harris; Aaron M Joffe; Michelle E Kho; John P Kress; Julie A Lanphere; Sharon McKinley; Karin J Neufeld; Margaret A Pisani; Jean-Francois Payen; Brenda T Pun; Kathleen A Puntillo; Richard R Riker; Bryce R H Robinson; Yahya Shehabi; Paul M Szumita; Chris Winkelman; John E Centofanti; Carrie Price; Sina Nikayin; Cheryl J Misak; Pamela D Flood; Ken Kiedrowski; Waleed Alhazzani
Journal:  Crit Care Med       Date:  2018-09       Impact factor: 7.598

4.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available.

Authors:  Miguel A Hernán; James M Robins
Journal:  Am J Epidemiol       Date:  2016-03-18       Impact factor: 4.897

5.  Propofol-induced pancreatitis: recurrence of pancreatitis after rechallenge.

Authors:  A N Kumar; D E Schwartz; K G Lim
Journal:  Chest       Date:  1999-04       Impact factor: 9.410

6.  Clinical Practice Guideline: Safe Medication Use in the ICU.

Authors:  Sandra L Kane-Gill; Joseph F Dasta; Mitchell S Buckley; Sandeep Devabhakthuni; Michael Liu; Henry Cohen; Elisabeth L George; Anne S Pohlman; Swati Agarwal; Elizabeth A Henneman; Sharon M Bejian; Sean M Berenholtz; Jodie L Pepin; Mathew C Scanlon; Brian S Smith
Journal:  Crit Care Med       Date:  2017-09       Impact factor: 7.598

7.  Use of an abnormal laboratory value-drug combination alert to detect drug-induced thrombocytopenia in critically Ill patients.

Authors:  Lisa M Harinstein; Sandra L Kane-Gill; Pamela L Smithburger; Colleen M Culley; Vivek K Reddy; Amy L Seybert
Journal:  J Crit Care       Date:  2012-04-18       Impact factor: 3.425

Review 8.  Propofol infusion syndrome in adults: a clinical update.

Authors:  Aibek E Mirrakhimov; Prakruthi Voore; Oleksandr Halytskyy; Maliha Khan; Alaa M Ali
Journal:  Crit Care Res Pract       Date:  2015-04-12

Review 9.  Clinical decision support for drug related events: Moving towards better prevention.

Authors:  Sandra L Kane-Gill; Archita Achanta; John A Kellum; Steven M Handler
Journal:  World J Crit Care Med       Date:  2016-11-04

Review 10.  Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports.

Authors:  Adéla Krajčová; Petr Waldauf; Michal Anděl; František Duška
Journal:  Crit Care       Date:  2015-11-12       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.